Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.
Saved in:
| Title: | Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. |
|---|---|
| Authors: | Cheema, P. K.1,2 parneet.cheema@sunnybrook.ca, Burkes, R. L.3,4 |
| Source: | Current Oncology. Apr2013, Vol. 20 Issue 2, pe150-e160. 11p. 3 Charts. |
| Database: | Academic Search Ultimate |
| ISSN: | 11980052 |
|---|---|
| DOI: | 10.3747/co.20.1226 |
